Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 2022

View Archived Issues

PILA identified as lncRNA that enhances NF-kappaB signaling and osteoarthritis

CNPY4 knockout embryos exhibit hedgehog signaling hyperactivation-driven defects

ATV-006, orally bioavailable antiviral candidate against SARS-CoV-2

Integral BioSciences patents ENPP1 inhibitors

Newave Pharmaceutical discloses new BTK inhibitors

Bivalent Epstein-Barr nanoparticle vaccine protects against infection in mice

Evusheld retains neutralization activity against SARS-CoV-2 Omicron BA.4 and BA.5 variants

Rhizen Pharmaceuticals divulges new PARP inhibitors

New EGFR inhibitors identified at Lengo Therapeutics

U.S. researchers present new NR1D2 agonists

CureVac and myNEO enter research and option agreement toward development of mRNA cancer vaccines

HotSpot and Excelra partner to support HotSpot's allosteric inhibitor candidate pipeline

Ellipses Pharma licenses rights to SunRock's bifunctional HER3:TRAIL fusion protein

PAI-1-TFT therapy shows promise for treating pleural empyema

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...